Skip to main navigation Skip to search Skip to main content

M15-991 a MultiCenter Randomized Double Blind Placebo Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Chron's Disease Who Failed Prior Biologic Treatment

Grants and Contracts Details

StatusFinished
Effective start/end date7/7/17 → 6/9/21

Funding

  • AbbVie Incorporated: $46,860.00